| Recruiting | DSLT for Reducing Medication in Glaucoma NCT07390890 | The Eye Institute of West Florida | — |
| Recruiting | Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use NCT07217678 | University of Miami | Phase 4 |
| Withdrawn | An Observational Study to Evaluate the ETX-4143 Device in Subjects With Ocular Hypertension NCT06709300 | EyeCool Therapeutics, Inc. | — |
| Recruiting | Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension NCT07335211 | Huons Co., Ltd. | Phase 3 |
| Recruiting | 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients NCT07325240 | Mayo Clinic | Phase 4 |
| Recruiting | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass NCT07218796 | SpyGlass Pharma, Inc. | Phase 3 |
| Recruiting | Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers NCT06629649 | University of Alabama at Birmingham | N/A |
| Recruiting | Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass NCT07218783 | SpyGlass Pharma, Inc. | Phase 3 |
| Not Yet Recruiting | GLAUcoma Diagnostic and Imaging Analysis (GLAUDIA) Study NCT07210216 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Active Not Recruiting | Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction NCT07082816 | Alcon Research | Phase 3 |
| Recruiting | Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma NCT07119580 | National Taiwan University Hospital | — |
| Not Yet Recruiting | Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry NCT04024293 | Sensimed AG | N/A |
| Active Not Recruiting | This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety NCT07081347 | Sanoculis Ltd | N/A |
| Recruiting | Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cata NCT07036510 | EyeD Pharma | Phase 1 |
| Recruiting | Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension NCT06964191 | PolyActiva Pty Ltd | Phase 2 |
| Completed | 24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring NCT06689696 | Smartlens, Inc. | — |
| Completed | Long-term Outcomes of Glaucoma Surgery in a Real-life Setting: the Agora Registry Study NCT06829810 | University Hospital, Bordeaux | — |
| Recruiting | A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China NCT06666855 | Santen Pharmaceutical Co., Ltd. | Phase 3 |
| Enrolling By Invitation | Long-term Vascular, Functional and Morphological Changes in Glaucoma and Ocular Hypertensive Patients NCT06827535 | Mario Stirpe | — |
| Recruiting | Long-term Safety and Efficacy of a Modified Suprachoroidal Silicone Tube (SST) Shunt NCT06691555 | Davinci LTD | — |
| Completed | Open-Label Study of Safety of H1337 in Healthy Volunteers NCT06572397 | D. Western Therapeutics Institute, Inc. | Phase 1 |
| Completed | Next Generation Rocklatan NCT06441643 | Alcon Research | Phase 2 |
| Not Yet Recruiting | Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT NCT06498440 | St. Joseph's Healthcare Hamilton | Phase 4 |
| Completed | Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients NCT06394973 | Laboratoires Thea | Phase 2 |
| Not Yet Recruiting | The A D A G I O Study NCT06455683 | Guy's and St Thomas' NHS Foundation Trust | — |
| Terminated | Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension NCT04500574 | Massachusetts Eye and Ear Infirmary | Phase 1 |
| Recruiting | A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Cli NCT06267274 | Amneal Pharmaceuticals, LLC | Phase 1 |
| Recruiting | Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population NCT05902871 | BelkinVision | N/A |
| Completed | EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS NCT06266351 | Intuor Technologies, Inc. | — |
| Unknown | A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TF NCT06177678 | Kukje Pharma | Phase 2 |
| Unknown | Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension NCT06152861 | Glaukos Corporation | Phase 2 |
| Completed | Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Ey NCT06144918 | Skye Bioscience, Inc. | Phase 2 |
| Active Not Recruiting | Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared t NCT06120842 | SpyGlass Pharma, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Travoprost Intraocular Implant in Conjunction With Cataract Surgery NCT06061718 | Glaukos Corporation | Phase 3 |
| Completed | Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension NCT05913232 | D. Western Therapeutics Institute, Inc. | Phase 2 |
| Active Not Recruiting | Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With NCT07154810 | SpyGlass Pharma, Inc. | — |
| Completed | Dorzolamide+Timolol Multidose Preservative-free vs Dorzolamida+Timolol BAK Preserved Efficacy and Safety NCT05857267 | Laboratorios Poen | Phase 4 |
| Completed | Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due NCT05495269 | Qlaris Bio, Inc. | Phase 2 |
| Terminated | Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma NCT05273385 | University of California, San Francisco | N/A |
| Unknown | Safety and Effectiveness of Drop-free Small Incision Cataract Surgery NCT05248139 | Visualiza | N/A |
| Unknown | A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients NCT05456724 | Theratocular Biotek Co. | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. NCT05389267 | Laboratoires Thea | Phase 1 / Phase 2 |
| Recruiting | Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in th NCT05401357 | Amneal Pharmaceuticals, LLC | Phase 3 |
| Completed | Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypert NCT05397600 | Laboratoires Thea | Phase 3 |
| Withdrawn | A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressur NCT04140279 | Bausch & Lomb Incorporated | Phase 4 |
| Completed | Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients Wit NCT07154797 | SpyGlass Pharma, Inc. | N/A |
| Recruiting | Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial NCT05844384 | 59th Medical Wing | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Ope NCT05335122 | Ocular Therapeutix, Inc. | Phase 2 |
| Completed | Study of a Latanoprost Ocular Implant for Treatment of Open Angle Glaucoma or Ocular Hypertension. NCT05333419 | PolyActiva Pty Ltd | Phase 1 |
| Unknown | Use of Nanodropper vs. Standard Eyedropper in Patients With Glaucoma and Ocular Hypertension NCT05277870 | University of Washington | N/A |
| Unknown | Study in Prostaglandin Associated Peri-orbitopathy Switching From Prostaglandin Monotherapy to Omidenepag Isop NCT05279716 | Santen Pharmaceutical Asia Pte. Ltd. | Phase 4 |
| Enrolling By Invitation | Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial NCT05159960 | Vastra Gotaland Region | N/A |
| Completed | A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension NCT05022004 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Completed | Evaluation of Nanodropper-mediated Microdrops vs. Standard Drops of 0.5% Timolol Maleate in Glaucoma Patients NCT05181046 | Nanodropper, Inc. | N/A |
| Unknown | A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension NCT04863365 | pH Pharma | Phase 3 |
| Terminated | Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® fo NCT04702789 | Laboratorios Sophia S.A de C.V. | Phase 4 |
| Completed | A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 NCT04947124 | Qlaris Bio, Inc. | Phase 2 |
| Withdrawn | Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population The Zhuiguang Trial NCT05043831 | BelkinVision | N/A |
| Recruiting | Inflammatory Biomarkers in Ocular Surface in Primary Open Angle Glaucoma or Ocular Hypertension Under Topical NCT05039684 | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | — |
| Recruiting | Effect of Benzalkonium Chloride Preserved and Preservative-free Latanoprost Eye Drops on Conjunctival Goblet C NCT04957329 | Rigshospitalet, Denmark | Phase 4 |
| Unknown | PSLT Compared to Prostaglandin Analogue Eye Drops NCT05241938 | Federal University of Rio Grande do Sul | N/A |
| Completed | To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glauco NCT04944290 | Padagis LLC | Phase 3 |
| Completed | Validation of an Automatic Analysis Algorithm of the Probability of Glaucoma From Optic Disc Images NCT04972695 | Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA | — |
| Completed | Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypert NCT04910100 | Betaliq, Inc. | Phase 2 |
| Completed | Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma o NCT04830397 | Qlaris Bio, Inc. | Phase 2 |
| Completed | Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Su NCT04401982 | University of Maryland, Baltimore | — |
| Suspended | Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension NCT04761705 | JeniVision, Inc. | Phase 1 / Phase 2 |
| Completed | Performance of the Travoprost Intraocular Implant NCT06582732 | Glaukos Corporation | Phase 2 |
| Unknown | Switching From the Preserved to the Preservative - Free Latanoprost - Timolol FC in Glaucoma Patients With OSD NCT04891588 | Klinički Bolnički Centar Zagreb | N/A |
| Completed | 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) NCT04647214 | Allergan | — |
| Completed | BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension NCT03235232 | EMS | Phase 3 |
| Completed | Study of LL-BMT1 in Patients With Elevated Intraocular Pressure NCT04747808 | MediPrint Ophthalmics, Inc. | Phase 2 |
| Completed | Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol NCT04742283 | Santen Inc. | Phase 2 |
| Completed | Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate NCT04620135 | Aerie Pharmaceuticals | Phase 3 |
| Recruiting | AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension NCT04499248 | AbbVie | Phase 1 / Phase 2 |
| Completed | MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCT04630808 | Nicox Ophthalmics, Inc. | Phase 3 |
| Unknown | Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients NCT04609345 | Santen Pharma Malaysia Sdn Bhd | — |
| Unknown | Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device NCT04595227 | Peking University | — |
| Unknown | FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular Hypertension NCT04585100 | Future Medicine | Phase 1 / Phase 2 |
| Withdrawn | Effect of Negative Pressure on Pattern Electroretinography Readings NCT04433702 | Vance Thompson Vision | N/A |
| Recruiting | MINIject Global Long-Term Follow-up Study NCT04524416 | iSTAR Medical | — |
| Terminated | Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear NCT04442464 | Mayo Clinic | N/A |
| Completed | A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients Wit NCT04285580 | AbbVie | Phase 3 |
| Unknown | A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 NCT04448223 | Chong Kun Dang Pharmaceutical | Phase 2 |
| Completed | Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latano NCT04405245 | EyePoint Pharmaceuticals, Inc. | Phase 2 |
| Unknown | 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucom NCT05299593 | Fondazione G.B. Bietti, IRCCS | Phase 4 |
| Completed | Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCT04445519 | Nicox Ophthalmics, Inc. | Phase 3 |
| Completed | iCare® Home vs Goldmann Applanation Tonometry NCT04911387 | St. Erik Eye Hospital | — |
| Completed | Safety and IOP-Lowering Effects of WB007 NCT04149899 | Bausch & Lomb Incorporated | Phase 1 / Phase 2 |
| Completed | Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects NCT03901781 | Noveome Biotherapeutics, formerly Stemnion | Phase 1 |
| Unknown | Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT) NCT04036214 | Northeastern State University | — |
| Completed | Retinal Effects of Balance Goggles System in Glaucoma Balance Goggles System (BGS) in Patients With Glaucoma NCT04035239 | Stanford University | Phase 1 |
| Completed | To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glauco NCT04024072 | Padagis LLC | Phase 3 |
| Withdrawn | A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular H NCT03927443 | Sun Pharmaceutical Industries Limited | Phase 3 |
| Withdrawn | Pilocarpine After Combined Cataract/Trabectome Surgery NCT04005079 | Montefiore Medical Center | Phase 3 |
| Completed | Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma NCT03960866 | Ocuphire Pharma, Inc. | Phase 2 |
| Completed | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solut NCT04284514 | Aerpio Therapeutics | Phase 1 |
| Completed | Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost NCT04743622 | CHA University | Phase 4 |
| Active Not Recruiting | Long-term Safety and Efficacy Extension Trial of Bimatoprost SR NCT03891446 | AbbVie | Phase 3 |
| Completed | Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle NCT03844945 | Aerie Pharmaceuticals | Phase 2 |
| Completed | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hype NCT03850782 | AbbVie | Phase 3 |
| Completed | Tafluprost Preservative Free Switch Study NCT04654611 | Tun Hussein Onn National Eye Hospital | Phase 4 |
| Active Not Recruiting | Optimal Treatment Protocol for Selective Laser Trabeculoplasty NCT03798223 | Vastra Gotaland Region | N/A |
| Completed | Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension NCT02617459 | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Phase 3 |
| Withdrawn | Prophylaxis for Anti-VEGF-induced IOP Elevation NCT02623023 | McMaster University | N/A |
| Completed | Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hyp NCT03808688 | Aerie Pharmaceuticals | Phase 4 |
| Unknown | A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 NCT03762369 | Chong Kun Dang Pharmaceutical | Phase 3 |
| Completed | Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients NCT03825380 | Laboratoires Thea | Phase 3 |
| Completed | A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty NCT03750201 | BelkinVision | N/A |
| Completed | Clinical Study Comparing Two Models of a Travoprost Intraocular Implant NCT03868124 | Glaukos Corporation | Phase 3 |
| Completed | Evaluation of Safety and Efficacy of PDP-716 NCT03450629 | Sun Pharma Advanced Research Company Limited | Phase 3 |
| Unknown | Comparing Refractive and Visual Outcomes of MIGS and Traditional Surgeries NCT03584958 | Wills Eye | — |
| Completed | Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Soluti NCT03519386 | Glaukos Corporation | Phase 3 |
| Completed | Is the Reduction in IOP After Treatment of 180 Degrees Equivalent to Treatment of 360 Degrees With SLT? NCT03529591 | Western University, Canada | N/A |
| Unknown | Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug -EXP-LP NCT03318146 | Shaare Zedek Medical Center | N/A |
| Completed | The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width NCT03926975 | University of Houston | N/A |
| Completed | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension NCT04360174 | Ocular Therapeutix, Inc. | Phase 1 |
| Recruiting | Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects NCT03870230 | Medical University of Vienna | N/A |
| Completed | Foot Reflexology in Ocular Hypertensive and Glaucoma Patients NCT04695314 | Temple University | N/A |
| Completed | A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of I NCT03293992 | Hoffmann-La Roche | Phase 1 |
| Completed | Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GAN NCT03284853 | Aerie Pharmaceuticals | Phase 3 |
| Completed | Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma NCT03131167 | Shire | Phase 1 |
| Terminated | Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma NCT02891317 | University of North Carolina, Chapel Hill | — |
| Unknown | Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily NCT03067415 | Chong Kun Dang Pharmaceutical | Phase 2 |
| Completed | Efficacy and Safety of ab Interno Trabeculectomy With the Kahook Dual Blade NCT04202562 | Hospital San Carlos, Madrid | N/A |
| Completed | Clinical Evaluation of CATS Tonometer Prism NCT02989909 | Intuor Technologies, Inc. | N/A |
| Completed | KJ-TFC-004 Drug-drug Interaction Study NCT02967614 | Kukje Pharma | Phase 1 |
| Completed | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT NCT02914509 | Ocular Therapeutix, Inc. | Phase 3 |
| Completed | Advanced Glycation End Products as a Biomarker for Accelerated Ageing NCT02863224 | University of Plymouth | — |
| Completed | Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution NCT02874846 | Aerie Pharmaceuticals | Phase 2 |
| Completed | Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hyperte NCT02796560 | Université de Sherbrooke | Phase 4 |
| Terminated | Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Ope NCT02858284 | EyeSonix | N/A |
| Unknown | Aqueous Dynamics and Glaucoma Surgeries NCT02839590 | Guy's and St Thomas' NHS Foundation Trust | — |
| Terminated | Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® NCT02730871 | Alcon Research | Phase 4 |
| Completed | Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Caps NCT03192826 | University Hospital of Patras | Phase 4 |
| Completed | A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on NCT03204487 | Ordination Dr. Hommer | Phase 4 |
| Completed | A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle G NCT02742649 | ForSight Vision5, Inc. | Phase 1 / Phase 2 |
| Completed | A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Effic NCT03419975 | Taejoon Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFOR NCT03257813 | Laboratorios Sophia S.A de C.V. | Phase 3 |
| Completed | A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma NCT02743780 | Alcon Research | Phase 1 / Phase 2 |
| Completed | SD-OCT Multimodal Analysis in GLaucoma NCT02710916 | University Hospital, Bordeaux | N/A |
| Completed | Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension NCT02674854 | Aerie Pharmaceuticals | Phase 3 |
| Completed | Surgical and Refractive Outcomes of Combined Glaucoma Surgery NCT04335825 | Medical University of Bialystok | N/A |
| Completed | A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Gl NCT02623738 | Santen Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension NCT02571712 | Allergan | Phase 4 |
| Terminated | Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Ten NCT01864317 | Medical University of Vienna | Phase 2 |
| Completed | Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension NCT02558400 | Aerie Pharmaceuticals | Phase 3 |
| Unknown | Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT NCT02585375 | Medical University of Vienna | Phase 4 |
| Unknown | A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma NCT02792803 | Dr. David Yan | Phase 4 |
| Completed | Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertens NCT02558374 | Aerie Pharmaceuticals | Phase 3 |
| Unknown | Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Micro NCT02471105 | Universitaire Ziekenhuizen KU Leuven | Phase 4 |
| Terminated | Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension NCT02801617 | Laboratorios Sophia S.A de C.V. | Phase 3 |
| Completed | Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open- NCT02507687 | AbbVie | Phase 3 |
| Completed | An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert NCT02537015 | ForSight Vision5, Inc. | Phase 2 |
| Completed | SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) NCT02419508 | Alcon Research | Phase 4 |
| Unknown | A Phase I Clinical Trial of DARC NCT02394613 | University College, London | Phase 1 |
| Completed | Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy NCT02434250 | University of Zurich | N/A |
| Completed | Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimon NCT02339584 | Alcon Research | Phase 3 |
| Unknown | Evaluation of Rate of Progression With Perimetry in Newly Diagnosed Open Angle Glaucoma NCT02379208 | Turku University Hospital | — |
| Completed | Dose-Ranging Study of the Bimatoprost Ocular Insert NCT02358369 | ForSight Vision5, Inc. | Phase 2 |
| Completed | Survey of Patients Taking IOP-Lowering Eye Drops NCT02384772 | ForSight Vision5, Inc. | — |
| Completed | Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Oc NCT02247804 | Allergan | Phase 3 |
| Completed | Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hyper NCT02250651 | Allergan | Phase 3 |
| Completed | Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COS NCT02325518 | Alcon, a Novartis Company | Phase 4 |
| Completed | Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients NCT02278614 | Laboratoires Thea | Phase 3 |
| Withdrawn | The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface NCT02295358 | University of Colorado, Denver | — |
| Completed | Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects NCT02312544 | Ocular Therapeutix, Inc. | Phase 2 |
| Completed | A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension NCT02348476 | Allergan | — |
| Completed | SYL040012, Treatment for Open Angle Glaucoma NCT02250612 | Sylentis, S.A. | Phase 2 |
| Completed | Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma NCT02338362 | University Health Network, Toronto | Phase 4 |
| Completed | Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension NCT02993445 | Temple University | N/A |
| Completed | Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension NCT02246764 | Aerie Pharmaceuticals | Phase 3 |
| Completed | Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study NCT02390245 | Wills Eye | N/A |
| Completed | 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma NCT02628223 | Temple University | N/A |
| Completed | The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressur NCT02165631 | University of Colorado, Denver | — |
| Completed | Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) NCT02167035 | Cornerstone Health Care, PA | Phase 4 |
| Completed | Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension NCT02207491 | Aerie Pharmaceuticals | Phase 3 |
| Completed | Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension NCT02207621 | Aerie Pharmaceuticals | Phase 3 |
| Completed | An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product NCT02143843 | ForSight Vision5, Inc. | Phase 2 |
| Completed | 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Gla NCT02140060 | Alcon Research | Phase 2 |
| Completed | Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With P NCT02179008 | Santen Inc. | Phase 2 |
| Completed | A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Gl NCT02102750 | Santen Oy | Phase 1 |
| Withdrawn | The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. NCT01927406 | Stanford University | Phase 4 |
| Completed | Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glauco NCT03534882 | Cindy Hutnik | N/A |
| Completed | A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glauco NCT02083289 | Ono Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latano NCT02129673 | ViSci Ltd. | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subje NCT02097719 | Allergan | Phase 4 |
| Completed | Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension NCT02105272 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension NCT02105285 | Otsuka Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertens NCT02136940 | Amakem, NV | Phase 2 |
| Completed | Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers NCT02108288 | Otsuka Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressur NCT02057575 | Aerie Pharmaceuticals | Phase 2 |
| Terminated | Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocula NCT02047630 | CHU de Quebec-Universite Laval | Phase 4 |
| Completed | Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hyper NCT02059278 | Nephron Pharmaceuticals Corporation | Phase 3 |
| Completed | Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure NCT02003391 | Alcon Research | Phase 4 |
| Terminated | IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patient NCT02030886 | Sensimed AG | N/A |
| Completed | A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma NCT02014142 | Mati Therapeutics Inc. | Phase 2 |
| Completed | Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose NCT02017327 | Laboratoires Thea | Phase 4 |
| Completed | A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a M NCT01999348 | Allergan | — |
| Completed | Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertensio NCT01915940 | ForSight Vision5, Inc. | Phase 2 |
| Completed | An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in NCT01979913 | Dr. Anton Hommer | Phase 4 |
| Completed | A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension NCT01943721 | ForSight Vision5, Inc. | Phase 1 |
| Completed | Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) NCT01975714 | Association for Innovation and Biomedical Research on Light and Image | Phase 4 |
| Completed | Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue NCT01937312 | Alcon Research | Phase 4 |
| Completed | Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertensio NCT01978600 | Alcon Research | Phase 4 |
| Completed | Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® NCT01937299 | Alcon Research | Phase 4 |
| Completed | Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients W NCT01995136 | Alcon Research | Phase 4 |
| Completed | A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0. NCT01936389 | Robert Ritch, MD, LLC. | Phase 2 |
| Completed | A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects NCT02003547 | Amakem, NV | Phase 1 |
| Completed | Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT NCT01895972 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects NCT01864642 | University of Wisconsin, Madison | N/A |
| Withdrawn | Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timo NCT01284166 | Allergan | Phase 3 |
| Completed | Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inad NCT01896180 | Alleanza Pharmaceuticals, Inc. | Phase 2 |
| Completed | A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension NCT01830140 | Allergan | Phase 3 |
| Completed | A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hyp NCT01863953 | Allergan | Phase 2 |
| Completed | An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Su NCT01881126 | Allergan | Phase 4 |
| Completed | A Study of Bimatoprost 0.01% in the Clinical Setting NCT01814761 | Allergan | — |
| Completed | A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherap NCT01853085 | Allergan | — |
| Completed | An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Sw NCT01735214 | Allergan | — |
| Completed | A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days NCT01789736 | Aerie Pharmaceuticals | Phase 2 |
| Withdrawn | Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia NCT01696383 | Alcon Research | Phase 4 |
| Unknown | IOP Lowering Effect of PLT Versus SLT in Naiv OAG Patients NCT01886456 | University of Zurich | N/A |
| Completed | Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocu NCT01749904 | Bausch & Lomb Incorporated | Phase 3 |
| Completed | Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertension NCT01987323 | Singapore Eye Research Institute | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients NCT01658839 | Alcon Research | Phase 1 |
| Completed | Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution NCT01749930 | Bausch & Lomb Incorporated | Phase 3 |
| Terminated | A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular NCT01781962 | Allergan | — |
| Withdrawn | Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH NCT01721707 | Adapt Produtos Oftalmológicos Ltda. | Phase 3 |
| Completed | Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Press NCT01731002 | Aerie Pharmaceuticals | Phase 2 |
| Completed | BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCT01707381 | Bausch & Lomb Incorporated | Phase 2 |
| Terminated | An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation NCT01719809 | Robin, Alan L., M.D. | — |
| Completed | A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular NCT01699464 | Aerie Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Long-term Observation of Ophthalmic Changes in Patients With Obstructive Sleep Apnea NCT03928665 | Wroclaw Medical University | — |
| Completed | Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension NCT03395535 | Moorfields Eye Hospital NHS Foundation Trust | Phase 4 |
| Completed | Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma NCT01693315 | Amakem, NV | Phase 2 |
| Completed | An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® NCT01664039 | Alcon Research | Phase 4 |
| Completed | ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular H NCT01668524 | Altheos, Inc. | Phase 2 |
| Completed | Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in NCT01739244 | Sylentis, S.A. | Phase 2 |
| Withdrawn | Ocular Hypertension And Yoga Study NCT01446588 | Johns Hopkins University | N/A |
| Completed | A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocula NCT01646151 | Allergan | — |
| Completed | Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion NCT01779778 | University of Colorado, Denver | — |
| Completed | A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) NCT01589510 | Allergan | — |
| Completed | A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension NCT01594970 | Allergan | Phase 4 |
| Completed | Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucom NCT01528111 | Lexicon Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of AR-13324 in Patients With Elevated Intraocular Pressure NCT01528787 | Aerie Pharmaceuticals | Phase 2 |
| Completed | Efficacy of Changing to TRAVATAN® From Prior Therapy NCT01510145 | Alcon Research | Phase 4 |
| Completed | Efficacy and Safety of the ExPRESS Implant Versus Deep Sclerectomy in Combined Surgery NCT03201354 | Institut Catala de Retina | N/A |
| Completed | Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) NCT01540370 | Allergan | — |
| Completed | A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Gl NCT01525173 | Allergan | Phase 4 |
| Unknown | Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hype NCT01520116 | Altheos, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Travacom Post Marketing Surveillance Study NCT01510132 | Alcon Research | Phase 4 |
| Completed | Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) NCT01547598 | Allergan | Phase 4 |
| Completed | Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect NCT01491867 | Semmelweis University | N/A |
| Completed | Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-245 NCT01254604 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure NCT01474135 | Aerie Pharmaceuticals | Phase 2 |
| Completed | Efficacy of Changing to TRAVATAN® From Prior Therapy NCT01493427 | Alcon Research | Phase 4 |
| Withdrawn | Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004% NCT01452009 | Alcon Research | Phase 3 |
| Unknown | Efficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical Prostaglandines NCT01467440 | University of Zurich | — |
| Unknown | Efficacy of Selective Laser Trabeculoplasty in Pseudophakic Patients NCT01467388 | University of Zurich | — |
| Completed | Travoprost 3-Month Safety and Efficacy Study NCT01453855 | Alcon Research | Phase 3 |
| Completed | Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension T NCT01464424 | Alcon Research | Phase 4 |
| Completed | Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertensi NCT01568008 | Allergan | — |
| Completed | Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hyp NCT01410188 | Kubota Vision Inc. | Phase 1 / Phase 2 |
| Completed | A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2% NCT01426867 | Alcon Research | Phase 2 |
| Unknown | Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost NCT01430923 | Aurolab | N/A |
| Completed | Patient Preference Comparison of AZARGA Versus COSOPT NCT01340014 | Alcon Research | Phase 4 |
| Completed | Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypert NCT01489670 | Allergan | — |
| Completed | Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada NCT01415401 | Alcon Research | Phase 4 |
| Completed | Efficacy of Changing to DUOTRAV® From Prior Therapy NCT01327599 | Alcon Research | Phase 4 |
| Completed | A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension NCT02020512 | Allergan | Phase 4 |
| Terminated | Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C NCT01312454 | Alcon Research | Phase 2 |
| Completed | Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension NCT01298700 | Allergan | Phase 4 |
| Completed | 24-hour Efficacy of AR-12286 NCT01330979 | Aerie Pharmaceuticals | Phase 2 |
| Completed | Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in NCT01309204 | Alcon Research | Phase 3 |
| Completed | DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solut NCT01342081 | Santen Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | DE-111 Against Timolol Ophthalmic Solution 0.5% NCT01342094 | Santen Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in P NCT01310777 | Alcon Research | Phase 3 |
| Completed | Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patient NCT01291108 | Allergan | Phase 2 |
| Completed | Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) NCT01162603 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Phase 4 |
| Completed | Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brin NCT01297920 | Alcon Research | Phase 3 |
| Completed | Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hyper NCT01241240 | Allergan | Phase 3 |
| Completed | Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy NCT01263444 | Alcon Research | Phase 4 |
| Completed | Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations NCT01306461 | Santen Oy | Phase 3 |
| Completed | Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2% NCT01297517 | Alcon Research | Phase 3 |
| Completed | Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies NCT01292460 | Santen Oy | Phase 3 |
| Completed | AR-12286 in Combination With Latanoprost NCT01302249 | Aerie Pharmaceuticals | Phase 2 |
| Completed | Divided Dose of TRAVATAN® NCT01298687 | Alcon Research | Phase 2 |
| Completed | 24-hour IOP-lowering Effect of 0.01% Bimatoprost NCT01271686 | University of California, San Diego | Phase 4 |
| Completed | Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension NCT01279083 | Santen Inc. | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hyper NCT01217606 | Allergan | Phase 3 |
| Completed | Long-Term Non-Interventional Latanoprost Study NCT01265719 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | — |
| Completed | Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hy NCT01253902 | Allergan | Phase 4 |
| Completed | Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or NCT01357616 | Alcon Research | Phase 3 |
| Completed | Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to NCT01254370 | Santen SAS | Phase 2 |
| Completed | Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension NCT00945958 | Sun Pharma Advanced Research Company Limited | Phase 3 |
| Completed | A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma ( NCT01628614 | Allergan | — |
| Completed | Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension NCT01216943 | Allergan | Phase 3 |
| Completed | Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hype NCT01229462 | Allergan | N/A |
| Completed | Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution NCT01215786 | Allergan | Phase 1 |
| Completed | SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure (IOP) >= 21 mm H NCT01227291 | Sylentis, S.A. | Phase 1 / Phase 2 |